Multidrug-resistant tuberculosis: Resistance rates to first and reserve antituberculosis drugs in the UK in 2008/9 and the role of rapid molecular tests for drug resistance

Thorax

Volumn 66, Issue 7, 2011, Pages 630-631

  Mitchell, S L ^a   Seoudi, N ^a   Hutchison, D C S ^a   Drobniewski, F A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; ETHAMBUTOL; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL;

EID: 79959308484     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2010.148866     Document Type: Letter

References (4)

1. Krüüner A, Yates MD, Drobniewski FA. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 2006;44:811-18.
2. Rüsch-Gerdes S, Pfyffer GE, Casal M, et al. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006;44:688-92.
3. Sam IC, Drobniewski F, More P, et al. Mycobacterium tuberculosis and rifampicin resistance, United Kingdom. Emerg Infect Dis 2006;12:752-9.
4. Tuberculosis in the UK. Annual report on tuberculosis surveillance in the UK 2009. London: Health Protection Agency Centre for Infections, 2009.